Zai Lab (NASDAQ: ZLAB)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.200 | -0.860 | 0.3400 | ||||
REV | 45.720M | 46.724M | 1.004M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Zai Lab (NASDAQ: ZLAB) through any online brokerage.
Other companies in Zai Lab’s space includes: Twist Bioscience (NASDAQ:TWST), Ultragenyx Pharmaceutical (NASDAQ:RARE), Karuna Therapeutics (NASDAQ:KRTX), Cerevel Therapeutics Hldg (NASDAQ:CERE) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Zai Lab (NASDAQ: ZLAB) was reported by Citigroup on Thursday, May 12, 2022. The analyst firm set a price target for 193.00 expecting ZLAB to rise to within 12 months (a possible 366.07% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Zai Lab (NASDAQ: ZLAB) is $41.41 last updated July 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Zai Lab.
Zai Lab’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Zai Lab.
Zai Lab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.